Radboud universitair medisch centrum / RADBOUDUMC — Clinical Trial Site

105 Registered trials

49 Currently recruiting

Organisation

Radboud universitair medisch centrum / RADBOUDUMC

Location

Nijmegen, Netherlands

Identifier

ORG-100031688

Address

Huispost 935, P. O. Box 9101, 6500 HB, Netherlands

Departments

-
#3702: Paediatrics
#3712: Cardiology
1304: Nephrology
1500: Medische Beeldvorming, sectie Nucleaire Geneeskunde
1501 :Medische Beeldvorming, sectie Nucleaire Geneeskunde
3702: Paediatrics
Afdeling Interne Geneeskunde
Amalia Children's Hospital, pediatrics
Anesthesiology
Cardiology
Department of Hematology
Department of Internal Medicine
Department of Surgery
Department Respiratory Diseases
Gastroenterology
Gastroenterology & Hepatology
Gastroenterology and Hepatology
Gynaecologische Oncologie
Hematology
Human Genetics
ICU
Intensive Care
Internal Medicine
Internal Medicine, division Infectious Diseases and Immunology
Laboratory Medical Immunology
Lung Oncology
Maag,- darm,- leverziekten
Medical Biosciences
Medical Imaging, Nuclear Medicine
Medical Oncology
Medische Oncologie
N/A
Nephrology
Neurology
Neuromuscular Unit
Neurosurgery
Nierziekten
NL10010, Maag, darm en leverziekten
Oncology
Ophthalmology
Otorhinolaryngology
Pediatrics
Pharmacy
Psychiatry
Pulmonary Diseases
Pulmonology
RADB
Radiotherapy
Research Facility
Research Unit Longziekten
Respiratory Diseases
Rheumatology
Surgery
Urology
Verloskunde & Gynaecologie
Ward (internal medicine)
Z97NL10002: Hematology

Clinical trials at this site (105)

Search interface

A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended

2023-506576-27-00 EGFR-mutated locally advanced or metastatic Non Small C 5 2020-09-30
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 5 2018-11-27
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Respiratory tract infection 5 2016-02-19
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Ended

2023-508606-26-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2015-04-23
PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f… Halted

2023-506194-35-00 Colorectal liver metastases 5 2024-11-21
A phase II trial to study the effectivity of combination immunotherapy in patients with prostate cancer (INSPIRE) Ended

2024-513186-39-01 castration-resistant prostate cancer 4 2025-02-01
IPAD Trial Ended

2024-513124-41-00 Primary antibody deficiency: - Unclassified antibody de 5 2024-07-12
AMX0035 and Progressive Supranuclear Palsy Ended

2023-505893-14-00 Progressive Supranuclear Palsy 5 2024-06-04
MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended

2023-506425-12-00 Uncontrolled and Resistant Hypertension 5 2024-04-17
A randomized double-blind placebo-controlled phase 1 study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single i… Ended

2023-507035-37-00 Circulatory shock 1 2024-03-11
A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD patients with myopathy and/or cardiomyopathy and inflammation (P… Ended

2023-508541-41-00 Primary Mitochondrial Disease 4 2023-05-22
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended

2023-506352-24-00 Non-obstructive Hypertrophic Cardiomyopathy 5 2023-04-13
REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in newly diagnosed PolyMyalgia Rheumatica Ended

2024-513544-28-00 Polymyalgia Rheumatica 6 2023-02-01
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
Phase 3 Study of Tinlarebant in the Treatment in Adolescent Stargardt Subjects Ended

2024-513483-26-00 Stargardt Disease 5 2022-11-28
A Phase 3 study to determine the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy (REACH) Ended

2024-512737-33-00 Facioscapulohumeral Muscular Dystrophy (FSHD) 5 2022-09-30
Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study Ended

2024-513635-24-00 oesophageal cancer 10 2022-09-29
A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm… Ended

2024-513658-31-00 Idiopathic Sudden Sensorineural Hearing Loss 4 2022-08-08
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patient… Ended

2024-514130-20-00 complement 3 glomerulopathy (C3G)/immune complex membr 5 2022-04-04
A study to evaluate the efficacy and safety of olorofim versus AmBisome® for treatment of invasive aspergillosis Ended

2024-513030-38-00 Invasive fungal infections due to Aspergillus spp. 5 2022-02-15
Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1 Ended

2024-514907-32-00 non-metastatic soft tissue sarcoma 3 2022-01-21
GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended

2024-510722-10-00 Malignant Solid Tumors 7 2021-12-13
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended

2024-512945-18-00 Geographic Atrophy Secondary to Age-Related Macular Deg 5 2021-11-30